Topiramate-induced modulation of hepatic molecular mechanisms: an aspect for its anti-insulin resistant effect.
Topiramate is an antiepileptic drug known to ameliorate insulin resistance besides reducing body weight. Albeit liver plays a fundamental role in regulation of overall insulin resistance, yet the effect of topiramate on this organ is controversial and is not fully investigated. The current work aimed to study the potential hepatic molecular mechanistic cassette of the anti-insulin resistance effect of topiramate. To this end, male Wistar rats were fed high fat/high fructose diet (HFFD) for 10 weeks to induce obese, insulin resistant, hyperglycemic animals, but with no overt diabetes. Two HFFD-groups received oral topiramate, 40 or 100 mg/kg, for two weeks. Topiramate, on the hepatic molecular level, has opposed the high fat/high fructose diet effect, where it significantly increased adiponectin receptors, GLUT2, and tyrosine kinase activity, while decreased insulin receptor isoforms. Besides, it improved the altered glucose homeostasis and lipid profile, lowered the ALT level, caused subtle, yet significant decrease in TNF-α, and boosted adiponectin in a dose dependent manner. Moreover, topiramate decreased liver weight/, visceral fat weight/, and epididymal fat weight/body weight ratios. The study proved that insulin-resistance has an effect on hepatic molecular level and that the topiramate-mediated insulin sensitivity is ensued partly by modulation of hepatic insulin receptor isoforms, activation of tyrosine kinase, induction of GLUT2 and elevation of adiponectin receptors, as well as their ligand, adiponectin, besides its known improving effect on glucose tolerance and lipid homeostasis.
Department of Pharmacology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Hanan S
HS
El-Abhar
Mona F
MF
Schaalan
D000704:Analysis of Variance; D000818:Animals; D059305:Diet, High-Fat; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005951:Glucose Tolerance Test; D051273:Glucose Transporter Type 2 / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology*; D050152:Intra-Abdominal Fat / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D054419:Receptors, Adiponectin / Q000378:metabolism; D000077236:Topiramate; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D051273:Glucose Transporter Type 2; D054419:Receptors, Adiponectin; C495683:Slc2a2 protein, rat; D014409:Tumor Necrosis Factor-alpha; D000077236:Topiramate; D005632:Fructose; D011505:Protein-Tyrosine Kinases